{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-139445","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.986428+00:00","generated_at":"2026-06-15T09:53:10.382047+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cytek Q1 revenue $37.1M (+6% YoY); net loss widens to $6.8M; organic revenue -4%; revises FY23 outlook to $205-220M","bullets":["Total revenue $37.1M, up 6% YoY; constant-currency revenue $38.1M (+9%).","Organic revenue (ex-Luminex) $33.7M, down 4% YoY; U.S. pharma/biotech weakness cited.","Net loss $6.8M vs $2.2M loss in Q1 2022; adjusted EBITDA -$2.5M vs +$1.9M.","Completed Luminex flow cytometry asset acquisition for $44.9M on Feb 28, 2023; contributed $3.4M revenue.","Revised FY2023 revenue guidance to $205-220M (25-34% growth), citing macro uncertainties and longer sales cycles."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-139445","json":"https://secwatch.observer/filing/0001193125-23-139445.json","markdown":"https://secwatch.observer/filing/0001193125-23-139445.md","text":"https://secwatch.observer/filing/0001193125-23-139445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523139445/0001193125-23-139445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523139445/d468414d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:53:10.382047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"847dc7fb9a8969a59c1834cb5299d818d33a7eb0","claim":"Cytek Biosciences, Inc. reported the first quarter ended March 31, 2023 results: revenue $37.1 million, net income $6.8 million.","evidence_excerpt":"First Quarter Highlights • Total revenue was $37.1 million, or $38.1 million on a constant currency basis, representing 6% and 9% increases respectively, over the first quarter of 2022. • Organic revenue for Cytek’s existing product portfolio was $33.7 million in the first quarter of 2023, representing a decline of 4% compared to the first quarter of 2022 • Revenue from the product lines acquired from Luminex Corporation, which closed February 28, 2023, was $3.4 million • Net loss was $6.8 million and adjusted EBITDA was $(2.5) million for the first quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523139445/0001193125-23-139445-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$37.1 million"},{"label":"Net income","value":"$6.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f894fc6944ecbed60e4d4b67f3f9622da4232a51","claim":"Cytek Biosciences, Inc. reported full year 2023 results: revenue $205 million to $220 million. Guidance lowered.","evidence_excerpt":"As a result of macro-economic uncertainties causing longer sales cycles, Cytek Biosciences has revised its full year 2023 revenue outlook and now expects total revenue to be in the range of $205 million to $220 million, representing growth of 25% to 34% over full year 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312523139445/0001193125-23-139445-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$205 million to $220 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}